Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma

Neuro-Oncology

Volumn 17, Issue 10, 2015, Pages 1344-1355

  Ramkissoon, Shakti H ^a,b   Bi, Wenya Linda ^b   Schumacher, Steven E ^a   Ramkissoon, Lori A ^a   Haidar, Sam ^a   Knoff, David ^a   Dubuc, Adrian ^b   Brown, Loreal ^a   Burns, Margot ^a   Cryan, Jane B ^b   Abedalthagafi, Malak ^b   Kang, Yun Jee ^a   Schultz, Nikolaus ^e   Reardon, David A ^a   Lee, Eudocia Q ^a   Rinne, Mikael L ^a   Norden, Andrew D ^a   Nayak, Lakshmi ^a   Ruland, Sandra ^a   Doherty, Lisa M ^a   Lafrankie, Debra C ^a   Horvath, Margaret ^a,b,c   Aizer, Ayal A ^a,b,c   Russo, Andrea ^d   Arvold, Nils D ^a,b,c   Claus, Elizabeth B ^b   Al Mefty, Ossama ^b   Johnson, Mark D ^b   Golby, Alexandra J ^b   Dunn, Ian F ^b   Chiocca, E Antonio ^b   Trippa, Lorenzo ^a   Santagata, Sandro ^b   Folkerth, Rebecca D ^b   Kantoff, Philip ^a   Rollins, Barrett J ^a   Lindeman, Neal I ^b   Wen, Patrick Y ^a   Ligon, Azra H ^b   Beroukhim, Rameen ^a,f   Alexander, Brian M ^a,b,c   Ligon, Keith L ^a,b   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

array CGH; clinical trials; genomics; genotyping; glioblastoma

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; SCATTER FACTOR RECEPTOR; TUMOR MARKER; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; PROTEIN P53; PTEN PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN TUMOR; CHILD; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL TRIAL (TOPIC); COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; EGFR GENE; EGFRVIII GENE; FEMALE; GENE; GENE AMPLIFICATION; GENE DELETION; GENE INACTIVATION; GENE LOCUS; GENOTYPE; GLIOBLASTOMA; HUMAN; IDH1 GENE; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MET GENE; MUTATIONAL ANALYSIS; PDGFRA GENE; PTEN GENE; TP53 GENE; TUMOR SUPPRESSOR GENE; BRAIN NEOPLASMS; COPY NUMBER VARIATION; GENE EXPRESSION PROFILING; GENETICS; GENOME-WIDE ASSOCIATION STUDY; INFANT; MIDDLE AGED; MUTATION; PRESCHOOL CHILD; PROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; GLIOBLASTOMA; HUMANS; INFANT; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; PROSPECTIVE STUDIES; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84940931907     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov015     Document Type: Article

References (38)

1. So D, Joly Y. Commercial opportunities and ethical pitfalls in personalized medicine: a myriad of reasons to revisit the myriad genetics saga. Curr Pharmacogenomics Person Med. 2013;11(2): 98-109.
2. McNamara MG, Sahebjam S, Mason WP. Emerging biomarkers in glioblastoma. Cancers. 2013;5(3):1103-1119.
3. Corless CL. Medicine. Personalized cancer diagnostics. Science. 2011;334(6060):1217-1218.
4. Network TCGA. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455(7216):1061-1068.
5. Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010; 463(7283):899-905.
6. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-615.
7. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet. 1998;20(2):207-211.
8. Nowak NJ, Miecznikowski J, Moore SR, et al. Challenges in array comparative genomic hybridization for the analysis of cancer samples. Genet Med. 2007;9(9):585-595.
9. Idbaih A, Criniere E, Ligon KL, et al. Array-based genomics in glioma research. Brain Pathol. 2010;20(1):28-38.
10. Craig JM, Vena N, Ramkissoon S, et al. DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. PloS One. 2012;7(6): e38881.
11. Dias-Santagata D, Lam Q, Vernovsky K, et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PloS One. 2011;6(3): e17948.
12. Chi AS, Batchelor TT, Dias-Santagata D, et al. Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol. 2012;110(1):89-98.
13. MacConaill LE, Campbell CD, Kehoe SM, et al. Profiling critical cancer gene mutations in clinical tumor samples. PloS One. 2009;4(11):e7887.
14. MacConaill LE, Garcia E, Shivdasani P, et al. Prospective enterprise-level molecular genotyping of a cohort of cancer patients. J Mol Diagn. 2014;16(6):660-672.
15. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401-404.
16. Firestein R, Bass AJ, Kim SY, et al. CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature. 2008; 455(7212):547-551.
17. Olshen AB, Venkatraman ES, Lucito R, et al. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics. 2004;5(4):557-572.
18. Mermel CH, Schumacher SE, Hill B, et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.
19. Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462-477.
20. Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2013;14(2):178-192.
21. Pinkel D, Albertson DG. Array comparative genomic hybridization and its applications in cancer. Nat Genet. 2005;37:(Suppl): S11-S17.
22. Louis DN, Wiestler OD, Cavenee WK. WHO Classification of Tumours of the Central Nervous System. Lyon: IARC; 2007.
23. Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 2003;63(20):6962-6970.
24. Bachoo RM, Maher EA, Ligon KL, et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell. 2002;1(3):269-277.
25. Zhu H, Acquaviva J, Ramachandran P, et al. Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci USA. 2009; 106(8):2712-2716.
26. Kastenhuber ER, Huse JT, Berman SH, et al. Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates. Acta Neuropathol. 2014;127(5):747-759.
27. Snuderl M, Fazlollahi L, Le LP, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell. 2011; 20(6):810-817.
28. Francis JM, Zhang CZ, Maire CL, et al. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov. 2014;4(8):956-971.
29. BeroukhimR, Getz G, Nghiemphu L, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA. 2007;104(50): 20007-20012.
30. Ramkissoon LA, Horowitz PM, Craig JM, et al. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci USA. 2013;110(20):8188-8193.
31. Reuss DE, Sahm F, Schrimpf D, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol. 2015;129(1):133-146.
32. Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol. 2014;24(5):429-435.
33. Jun HJ, Bronson RT, Charest A. Inhibition of EGFR induces a c-MET driven stem cell population in glioblastoma. Stem Cells. 2014; 32(2):338-348.
34. Balss J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathologica. 2008;116(6): 597-602.
35. Kannan K, Inagaki A, Silber J, et al. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget. 2012;3(10):1194-1203.
36. Cryan JB, Haidar S, Ramkissoon LA, et al. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget. 2014; 5(18):8083-8092.
37. Alexander BM, Galanis E, Yung WK, et al. Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro Oncol. 2015;17(2): 180-188.
38. Conley BA, Doroshow JH. Molecular analysis for therapy choice: NCI MATCH. Semin Oncol. 2014;41(3):297-299.